戻る
Supernus Pharmaceuticals Inc (SUPN)価格
SUPN 株価推移チャート
SUPN 収入
Supernus Pharmaceuticals Inc
$50.84
1.98%
$0.99
終値： Feb 13, 16:00:00 GMT-5
$50.84
0%
$0
アフターマーケット：Feb 13, 16:42:00 GMT-5
主要データ
前終値
$49.85
始値
$49.85
当日レンジ
$49.46 - $51.4
52週レンジ
$29.16 - $57.65
取引高
681.3K
平均取引高
670.9K
1株当たり利益(TTM)
-0.34
配当利回り
--
時価総額
$2.9B
SUPNとは何ですか？
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 674 full-time employees. The company went IPO on 2010-12-28. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. The company also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.